JAK inhibition decreases the autoimmune burden in Down syndrome

    December 2024 in “ eLife ”
    Angela L. Rachubinski, Elizabeth Wallace, Emily Gurnee, Belinda A Enriquez-Estrada, Kayleigh R Worek, Keith P. Smith, Paula Araya, Katherine A. Waugh, Ross E. Granrath, Eleanor Britton, Hannah R. Lyford, Micah G. Donovan, Neetha Paul Eduthan, Amanda A. Hill, Barry Martin, Kelly D. Sullivan, Lina Patel, Deborah J. Fidler, Matthew D. Galbraith, Cory A. Dunnick, David A. Norris, Joaquı́n M. Espinosa
    TLDR JAK inhibition reduces autoimmune issues in Down syndrome.
    The study investigates the impact of JAK inhibition, specifically using the JAK inhibitor tofacitinib, on autoimmune conditions in individuals with Down syndrome (DS). Conducted through a Phase II clinical trial with hundreds of participants, including an interim analysis of 10 participants, the research found that tofacitinib effectively reduced skin pathology in conditions like alopecia areata, psoriasis, and atopic dermatitis. It also decreased interferon and cytokine scores and levels of pathogenic autoantibodies without causing significant immune suppression. The findings suggest that JAK inhibition is a promising strategy for treating autoimmune conditions in DS, although further research is needed to explore its broader effects on DS's developmental and clinical features.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results